We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis. We are developing first-in-class small molecules that are focused on a unique target with the potential to fully normalize CFTR function for the first time for the vast majority of people living with CF.

Atlas Venture

OrbiMed

T. Rowe Price

Cystic Fibrosis Foundation

The Rise Fund

TPG Rise Climate Fund

RA Capital Management

Sionna Therapeutics

Managing a cystic fibrosis (#CF) diagnosis can be challenging. Jennifer, whose child is living with CF, has found ways to make the diagnosis less overwhelming. Read about her journey here: https://lnkd.in/dExcKR4g

At Sionna, we exercise our Core Values through our quarterly Culture Blasts. These events provide a way for us to come together regularly, learn about ourselves, practice our leadership skills and celebrate our achievements! 

During our most recent #CultureBlast in March, we had a great time celebrating our successful Series C financing and engaging in team bonding activities. Check out some pictures from the event!  

Just a few weeks after closing our Series C round, President & CEO Michael Cloonan reflected on the process of a private funding round and the key drivers of success including science, relationships and experience.  
 
Find the full post on the "From The Trenches" LifeSciVC blog organized by Bruce Booth of Atlas Venture: https://lnkd.in/es4mmfCz

We take calculated risks and purposefully explore creative ways to raise the bar for people living with cystic fibrosis (CF). In line with our core value of Intentional Innovation, Juliet Labadorf, Senior Director, Financial Planning & Analysis, shares a message about Sionna’s dynamic approach to CF therapeutic development.  

We are committed to the collective well-being of our entire team. That’s why we value flexibility, prioritize employee-driven ways of working, and offer policies designed to enhance work/life balance. 

Learn more about life at Sionna: https://lnkd.in/etdzEAVY 

Vertex Pharmaceuticals is a leading biotechnology company that has marketed medicines for cystic fibrosis.

Vertex Pharmaceuticals

Mediar Therapeutics is a competitor of Sionna Therapeutics in the development of cystic fibrosis therapies.

Mediar Therapeutics

Pliant is a competitor of Sionna Therapeutics in the field of cystic fibrosis therapies.

Pliant

Alentis Therapeutics is a competitor of Sionna Therapeutics in the development of therapies for cystic fibrosis.

Alentis Therapeutics

Blade Therapeutics competes with Sionna Therapeutics in the field of cystic fibrosis therapies.

Blade Therapeutics

Reneo Pharmaceuticals is a competitor of Sionna Therapeutics in the field of cystic fibrosis therapies.

Reneo Pharmaceuticals

Arcturus Therapeutics competes with Sionna Therapeutics in the field of cystic fibrosis therapies.

Arcturus Therapeutics

A biotechnology company focused on developing therapies to fully normalize CFTR function, targeting the NBD1, ICL4, and TMD1 regions of CFTR to achieve best-in-class efficacy for patients with cystic fibrosis.

Co-founder and SVP Head of Research

Head Protein Conformational Diseases Research

Head Rare Pulmonary Research - RD Director/Associate Director/Senior Principal Scientist

Senior Scientist / Staff Scientist II / Staff Scientist

Adjunct Faculty - Graduate School of Biomedical Sciences

Post Doctoral Fellow

Ph.D. Student

Co-founder and SVP Head of Research - Sionna Therapeutics

Greg Hurlbut

Senior Director Data Management

Director Data Management

Director Data Management and Programming

Associate Director Data Management

Manager Data Management

Senior Director Data Management, Sionna Therapeutics

Jamie Kistner

Senior Director of Financial Planning & Analysis

Director of Financial Planning & Analysis

Associate Director, Corporate Finance

Senior Manager, Financial Planning & Analysis

Manager, FP&A

Financial Analyst, FP&A

Senior in Distribution Operations & Reporting

Distribution Operations & Reporting

Audit Senior Assistant

Audit & Assurance Intern

Senior Director of Corporate Finance

Juliet Labadorf

Director

Associate Director

Senior Principal Scientist

Principal Scientist

Senior Scientist

Staff Scientist II

Staff Scientist I

Senior Research Chemist I

Senior Resear Chemist

Experienced Medicinal Chemist

Junkai Liao

Chief Financial Officer & Head of Corporate Development

Board Member

Executive Vice President, Chief Financial Officer

Senior Vice President, Investor Relations and Interim Chief Financial Officer

Senior Vice President, Investor Relations

Vice President, Investor Relations

Executive Director, Investor Relations

Chief Financial Officer & Head of Corporate Development, Sionna Therapeutics

Elena Ridloff

Chief People Officer

EVP, Chief Human Resources Officer

SVP, Head of Human Resources

VP, Head of Human Resources

HR Business Partner, R&D

HR Business Partner to CFO/Finance

Talent Acquisition Leader, R&D, PO&T, IT & CF

Administrative Director, Department of Neurology - Clinical Operations, Quality & Safety, Education

Director, Department of Neurology - Education and Training

Manager, Department of Neurology - Education Programs

Chief People Officer at Sionna Therapeutics

Vanya Sagar

Director, Medicinal Chemistry

Senior Research Investigator

Preclinical Science Consultant

Research Investigator, Lead Optimization

Senior Research Scientist, Lead Optimization

Research Scientist, Medicinal Chemistry

Medicinal Chemist

George Topalov

Director of Clinical Operations

Associate Director of Clinical Operations

Associate Director, Clinical Operations Team Leader, US

Sr. Clinical Study Leader

Manager Clinical Operations

Clinical Trial Manager

Sr. Clinical Research Associate

Clinical Research Associate

Clinical Research Coordinator

Clinical Trial Coordinator I

Leasing Agent

Marketing Assistant

Director of Clinical Operations  at Sionna Therapeutics

Jessica Hauben

Chief Medical Officer at Sionna Therapeutics; Leadership Council, International Institute

VP, Cystic Fibrosis and AAT Clinical Development

VP Clinical Development

Vice President, Clinical Development and Medical Affairs

Senior Medical Director

Director, Experimental Medicine/Translational Research

Associate Director, Experimental Medicine

Fellow, Pulmonary and Critical Care Medicine

Intern and Resident, Internal Medicine

Associate Physician

Chief Medical Officer at Sionna Therapeutics; Leadership Council, International Institute of New England

Charlotte McKee

Associate Director, Program Management

Sr. Operations Manager, Nonclinical Development

Manager, Nonclinical Operations

Client Services / Business Development

Contract Administrator

Chemist

TEACHING EXPERIENCE

Research Assistant

Associate Director, Program Management at Sionna Therapeutics

Melissa Medeiros

Director, Head of Starting Materials

Senior Director, Head of Process Chemistry

Director, Process Chemistry

Scientist II

Founder and Owner

Scientist

Research Investigator I

NIH Postdoctoral Fellow

Graduate Student

Director, Head of Starting Materials, Innovative CMC Leader

Gerald Artman

Co-founder and Vice President of Medicinal Chemistry

Head of Medicinal Chemistry, North America

Director of Medicinal Chemistry

Senior Group Leader

Group Leader

Research Scientist II

Research Scientist I

Intern

Co-founder and Vice President of Medicinal Chemistry at Sionna Therapeutics

Mark M.

Senior Director, Corporate Controller

Director, Corporate Controller

Associate Director, Accounting

Assurance Senior

ITRA (IT Risk and Assurance) Intern

Senior Director, Corporate Controller at Sionna Therapeutics

Erica Iorio

President and Chief Executive Officer

Chief Operating Officer

Chief Business Officer

Senior Vice President, US Commercial

Senior Vice President, Global Commercial Strategy

VP, Managing Director

Vice President, Finance

Director, Business Planning

President and Chief Executive Officer, Sionna Therapeutics

Michael Cloonan

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

news impact assignment basic	general	May 4, 2024 5:33 AM	20d49163
public peers	general	May 4, 2024 5:33 AM	da6c708e
news daily refresh	general	Sep 1, 2024 10:00 AM	66a16f11
news processing daily refresh	general	Sep 2, 2024 9:51 AM	04600232
news impact assignment daily	general	Sep 3, 2024 9:56 AM	56d394b0
news processing basic	general	May 4, 2024 5:33 AM	9cdbd552
company summary	general	Aug 25, 2024 5:46 PM	34342dcd
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	May 4, 2024 5:33 AM	f1daa1cb
translate crunchbase fundingrounds	general
peers	general
news basic	general	May 4, 2024 5:33 AM	f5f9e822
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:SIONNATX

Sionna Therapeutics